Your browser doesn't support javascript.
loading
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors.
Muller, Mirte; Hummelink, Karlijn; Hurkmans, Daan P; Niemeijer, Anna-Larissa N; Monkhorst, Kim; Roder, Joanna; Oliveira, Carlos; Roder, Heinrich; Aerts, Joachim G; Smit, Egbert F.
Afiliação
  • Muller M; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hummelink K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hurkmans DP; Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Niemeijer AN; Department of Pulmonary Diseases, Vrije Universiteit VU Medical Center, Amsterdam, the Netherlands.
  • Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Roder J; Biodesix, Boulder, Colorado.
  • Oliveira C; Biodesix, Boulder, Colorado.
  • Roder H; Biodesix, Boulder, Colorado.
  • Aerts JG; Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. e.smit@nki.nl.
Clin Cancer Res ; 26(19): 5188-5197, 2020 10 01.
Article em En | MEDLINE | ID: mdl-32631957
ABSTRACT

PURPOSE:

Pretreatment selection of patients with non-small cell lung cancer (NSCLC) who would derive clinical benefit from treatment with immune checkpoint inhibitors (CPIs) would fulfill an unmet clinical need by reducing unnecessary toxicities from treatment and result in substantial health care savings. EXPERIMENTAL

DESIGN:

In a retrospective study, mass spectrometry (MS)-based proteomic analysis was performed on pretreatment sera derived from patients with advanced NSCLC treated with nivolumab as part of routine clinical care (n = 289). Machine learning combined spectral and clinical data to stratify patients into three groups with good ("sensitive"), intermediate, and poor ("resistant") outcomes following treatment in the second-line setting. The test was applied to three independent patient cohorts and its biology was investigated using protein set enrichment analyses (PSEA).

RESULTS:

A signature consisting of 274 MS features derived from a development set of 116 patients was associated with progression-free survival (PFS) and overall survival (OS) across two validation cohorts (N = 98 and N = 75). In pooled analysis, significantly better OS was demonstrated for "sensitive" relative to "not sensitive" patients treated with nivolumab; HR, 0.58 (95% confidence interval, 0.38-0-87; P = 0.009). There was no significant association with clinical factors including PD-L1 expression, available from 133 of 289 patients. The test demonstrated no significant association with PFS or OS in a historical cohort (n = 68) of second-line NSCLC patients treated with docetaxel. PSEA revealed proteomic classification to be significantly associated with complement and wound-healing cascades.

CONCLUSIONS:

This serum-derived protein signature successfully stratified outcomes in cohorts of patients with advanced NSCLC treated with second-line PD-1 CPIs and deserves further prospective study.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Sanguíneas / Carcinoma Pulmonar de Células não Pequenas / Antígeno B7-H1 / Inibidores de Checkpoint Imunológico Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Sanguíneas / Carcinoma Pulmonar de Células não Pequenas / Antígeno B7-H1 / Inibidores de Checkpoint Imunológico Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article